{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:33:06Z","timestamp":1793395986030,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.bmcl.2026.130601","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T08:11:42Z","timestamp":1772093502000},"page":"130601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Structure\u2013activity relationship\u2013driven lead optimization of pyrazole hydrazide\u2013hydrazone analogues as potent antimycobacterial agents: in vitro and in silico studies"],"prefix":"10.1016","volume":"136","author":[{"given":"Pardeep","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Singampalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Bandela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Mounika","family":"Bellapukonda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishna","family":"Kodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhendu","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laxma Naik","family":"Korra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Devi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin Pal","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas","family":"Nanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkata Madhavi","family":"Yaddanapudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130601_bb0005","series-title":"Global Tuberculosis Report","year":"2024"},{"key":"10.1016\/j.bmcl.2026.130601_bb0010","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41572-024-00504-2","article-title":"Multidrug-resistant tuberculosis","volume":"10","author":"Dheda","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.bmcl.2026.130601_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116785","article-title":"Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment","volume":"277","author":"Wei","year":"2024","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0020","series-title":"Tuberculosis Is a Fatal Disease among some Developing Countries of the World","author":"Mohajan","year":"2014"},{"key":"10.1016\/j.bmcl.2026.130601_bb0025","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/s41579-024-01025-1","article-title":"Drug-resistant tuberculosis: a persistent global health concern","volume":"22","author":"Farhat","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2026.130601_bb0030","article-title":"The progress of mycobacterium tuberculosis drug targets","volume":"11","author":"Zhang","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.bmcl.2026.130601_bb0035","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bmcl.2026.130601_bb0040","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1128\/AAC.00749-08","article-title":"New drugs against tuberculosis: problems, Progress, and evaluation of agents in clinical development","volume":"53","author":"Van Den Boogaard","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130601_bb0045","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.19.2.382-402.2006","article-title":"Clinically relevant chromosomally encoded multidrug resistance efflux pumps in Bacteria","volume":"19","author":"Piddock","year":"2006","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.bmcl.2026.130601_bb0050","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJMp068273","article-title":"XDR tuberculosis \u2014 implications for global public health","volume":"356","author":"Raviglione","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2026.130601_bb0055","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between Clofazimine and Bedaquiline through upregulation of MmpL5 in mycobacterium tuberculosis","volume":"58","author":"Hartkoorn","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130601_bb0060","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1183\/09031936.00145714","article-title":"High tuberculosis burden among people living with HIV in southern Mozambique","volume":"45","author":"Garc\u00eda-Basteiro","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.bmcl.2026.130601_bb0065","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00239-17","article-title":"Primary Clofazimine and Bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis","volume":"61","author":"Xu","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130601_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1441147","article-title":"Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement","volume":"15","author":"Sankar","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmcl.2026.130601_bb0075","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/35016103","article-title":"A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis","volume":"405","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130601_bb0080","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of several novel Oxazolidinones against mycobacterium tuberculosis in a murine model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130601_bb0085","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tube.2017.12.006","article-title":"Mechanisms of resistance to delamanid, a drug for mycobacterium tuberculosis","volume":"108","author":"Fujiwara","year":"2018","journal-title":"Tuberculosis"},{"key":"10.1016\/j.bmcl.2026.130601_bb0090","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.5588\/ijtld.15.0864","article-title":"Detection of <I>kat<\/I>G and <I>inh<\/I>A mutations to guide isoniazid and ethionamide use for drug-resistant tuberculosis","volume":"20","author":"Bollela","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.bmcl.2026.130601_bb0095","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1128\/AAC.47.12.3799-3805.2003","article-title":"ethA, inhA, and katG loci of ethionamide-resistant clinical mycobacterium tuberculosis isolates","volume":"47","author":"Morlock","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmcl.2026.130601_bb0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/ph14040361","article-title":"New InhA inhibitors based on expanded Triclosan and Di-Triclosan analogues to develop a new treatment for tuberculosis","volume":"14","author":"Chetty","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bmcl.2026.130601_bb0105","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.201800025","article-title":"Discovery of a cofactor-independent inhibitor of mycobacterium tuberculosis InhA","volume":"1","author":"Xia","year":"2018","journal-title":"Life Sci Alliance"},{"key":"10.1016\/j.bmcl.2026.130601_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.nexres.2026.101391","article-title":"Activity landscape modeling of InhA inhibitors: characterizing potency variations through structural similarity","volume":"6","author":"Jalala","year":"2026","journal-title":"Next Res"},{"key":"10.1016\/j.bmcl.2026.130601_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500079","article-title":"Is mycobacterial InhA a suitable target for rational drug design?","volume":"20","author":"Rizet","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0120","doi-asserted-by":"crossref","DOI":"10.1007\/s44371-025-00367-w","article-title":"In silico design and evaluation of novel anti-tubercular agents as Inha inhibitors through a virtual screening approach","volume":"2","author":"Nyijime","year":"2025","journal-title":"Discov Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0125","doi-asserted-by":"crossref","DOI":"10.1007\/s13659-025-00576-x","article-title":"Discovery of pyridomycin derivatives as InhA inhibitors from actinomycetes through molecular networking and an in-house tandem mass library","volume":"16","author":"Lee","year":"2026","journal-title":"Nat Prod Bioprospect"},{"key":"10.1016\/j.bmcl.2026.130601_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.106434","article-title":"Structure-based drug design of novel M. Tuberculosis InhA inhibitors based on fragment molecular orbital calculations","volume":"152","author":"Phusi","year":"2023","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.bmcl.2026.130601_bb0135","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1080\/17568919.2025.2525069","article-title":"Exploration of pyrazole-based pyridine-4-carbohydrazide derivatives as drug-resistant Mtb agents: design, synthesis, biological evaluation, and in-silico studies","volume":"17","author":"Kumar","year":"2025","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/slct.202501301","article-title":"Exploration of pyridine-4-hydrazide derivatives as promising antitubercular agents: synthesis, biological evaluation, and in silico studies","volume":"10","author":"Kumar","year":"2025","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bmcl.2026.130601_bb0145","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.ejmech.2018.04.017","article-title":"New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: synthesis, antimycobacterial activity and investigation of their mechanism of action","volume":"151","author":"Vos\u00e1tka","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0150","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1002\/ejoc.201300901","article-title":"An approach to 2,4-substituted pyrazolo[1,5-a]pyridines and pyrazolo[1,5-a]azepines by ring-closing metathesis","author":"Fustero","year":"2013","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000349","article-title":"Design, synthesis, in silico, and in vitro evaluation of 3-phenylpyrazole acetamide derivatives as antimycobacterial agents","volume":"354","author":"Gaikwad","year":"2021","journal-title":"Arch Pharm"},{"key":"10.1016\/j.bmcl.2026.130601_bb0160","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4103\/0975-7406.171694","article-title":"Current status of pyrazole and its biological activities","volume":"8","author":"Naim","year":"2016","journal-title":"J Pharm Bioallied Sci"},{"key":"10.1016\/j.bmcl.2026.130601_bb0165","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.bmcl.2017.01.087","article-title":"Design, synthesis and evaluation of novel pyrazolo-pyrimido[4,5-d]pyrimidine derivatives as potent antibacterial and biofilm inhibitors","volume":"27","author":"Suresh","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130601_bb0170","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jscs.2015.08.001","article-title":"Ionic liquid catalysed multicomponent synthesis, antifungal activity, docking studies and in silico ADMET properties of novel fused chromeno-pyrazolo-phthalazine derivatives","volume":"21","author":"Sagar Vijay Kumar","year":"2017","journal-title":"J Saudi Chem Soc"},{"key":"10.1016\/j.bmcl.2026.130601_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130462","article-title":"Design, synthesis, \u03b1-glucosidase inhibitory activity, and molecular docking of novel pyrazolyl\u2013porphyrin hybrids as potential antidiabetic agents","volume":"131","author":"Peddakotla","year":"2026","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130601_bb0180","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jfluchem.2012.11.008","article-title":"Synthesis of diversely fluorinated pyrazoles as novel active agrochemical ingredients","volume":"152","author":"Giornal","year":"2013","journal-title":"J Fluor Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0185","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s11030-023-10612-y","article-title":"Design and synthesis of some novel hybrid molecules based on 4-thiazolidinone bearing pyridine-pyrazole scaffolds: molecular docking and molecular dynamics simulations of its major constituent onto DNA gyrase inhibition","volume":"28","author":"Desai","year":"2024","journal-title":"Mol Divers"},{"key":"10.1016\/j.bmcl.2026.130601_bb0190","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1021\/ml200091q","article-title":"Discovery of potent dual PPAR\u03b1 agonists\/CB1 ligands","volume":"2","author":"P\u00e9rez-Fern\u00e1ndez","year":"2011","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130601_bb0195","doi-asserted-by":"crossref","first-page":"5114","DOI":"10.2174\/092986711797636090","article-title":"The state of the art of Pyrazole derivatives as monoamine oxidase inhibitors and antidepressant\/anticonvulsant agents","volume":"18","author":"Secci","year":"2011","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0200","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.2174\/13895575113139990078","article-title":"Pyrazole derivatives as antitumor, anti-inflammatory and antibacterial agents","volume":"13","author":"Liu","year":"2013","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0205","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.ejmech.2017.11.098","article-title":"Development of novel bis-pyrazole derivatives as antitumor agents with potent apoptosis induction effects and DNA damage","volume":"143","author":"Dai","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0210","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejmech.2014.03.033","article-title":"Synthesis, structure-activity relationships, and in vitro antibacterial and antifungal activity evaluations of novel pyrazole carboxylic and dicarboxylic acid derivatives","volume":"78","author":"Mert","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0215","first-page":"940","article-title":"Recent advances in synthesis and properties of pyrazoles","volume":"4","author":"R\u00edos","year":"2022","journal-title":"Chemistry (Switzerland)"},{"key":"10.1016\/j.bmcl.2026.130601_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117081","article-title":"Antibacterial and antifungal pyrazoles based on different construction strategies","volume":"282","author":"Rehman","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0225","first-page":"1","article-title":"Exploration of pyrazole-based pyridine-4-carbohydrazide derivatives as drug-resistant Mtb agents: design, synthesis, biological evaluation, and in-silico studies","author":"Kumar","year":"2025","journal-title":"Future Med Chem"},{"key":"10.1016\/j.bmcl.2026.130601_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.70074","article-title":"Exploration of new dihydroindazole derivatives as promising anti-TB agents: design, synthesis, in silico, and biological evaluation","volume":"358","author":"Kumar","year":"2025","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.bmcl.2026.130601_bb0235","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bmcl.2018.12.065","article-title":"Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes","volume":"29","author":"He","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2026.130601_bb0240","doi-asserted-by":"crossref","first-page":"24830","DOI":"10.1021\/acs.jmedchem.5c02894","article-title":"Fragment-to-lead medicinal chemistry publications in 2024: a tenth annual perspective","volume":"68","author":"Twigg","year":"2025","journal-title":"J Med Chem"}],"container-title":["Bioorganic &amp; Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26000685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:31:00Z","timestamp":1774974660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26000685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"alternative-id":["S0960894X26000685"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130601","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure\u2013activity relationship\u2013driven lead optimization of pyrazole hydrazide\u2013hydrazone analogues as potent antimycobacterial agents: in vitro and in silico studies","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130601"}}